Regeneron Pharmaceuticals, Inc [REGN] stock prices are up 2.27% to $571.54 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REGN shares have gain 2.31% over the last week, with a monthly amount glided 4.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on June 30, 2025, when Argus downgraded its rating to a Hold. Previously, Wells Fargo downgraded its rating to Equal Weight on May 30, 2025, and kept the price target unchanged to $580. On May 30, 2025, downgrade downgraded it’s rating to Sector Perform but maintained its price target of $662 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $700 on May 14, 2025. Leerink Partners upgraded its rating to Outperform for this stock on February 05, 2025, and upped its price target to $834. In a note dated January 16, 2025, UBS downgraded an Neutral rating on this stock and revised its target price from $1130 to $738.
The stock price of Regeneron Pharmaceuticals, Inc [REGN] has been fluctuating between $476.49 and $1211.20 over the past year. Currently, Wall Street analysts expect the stock to reach $716.57 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $571.54 at the most recent close of the market. An investor can expect a potential return of 25.38% based on the average REGN price forecast.
Analyzing the REGN fundamentals
The Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] reported sales of 14.21B for trailing twelve months, representing a surge of 3.62%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.14 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Regeneron Pharmaceuticals, Inc [NASDAQ:REGN]’s Current Ratio is 4.60. As well, the Quick Ratio is 3.72, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 4.26, the price to book ratio is 2.03 and price to earnings (TTM) ratio is 14.40.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
